Review on: Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy
Journal of Cancer Treatment and Research
Volume 7, Issue 4, December 2019, Pages: 69-76
Received: Jul. 23, 2019; Accepted: Sep. 9, 2019; Published: Dec. 26, 2019
Views 141      Downloads 61
Author
Getu Melesie Taye, Department of Pharmacy, Ambo University, Ambo, Ethiopia
Article Tools
Follow on us
Abstract
Cancer is the second leading cause of mortality and it is a worldwide public health issue and has severe social and economic consequences. Cancer arises through a multistep, mutagenic process whereby cancer cells acquire a common set of properties including unlimited proliferation potential, self-sufficiency in growth signals, and resistance to anti-proliferative and apoptotic signals. Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of the improvements in the life quality of patients, their effectiveness is compromised by several disadvantages. Better understanding of the pathogenesis of this disease, identification of molecular targets for therapeutic intervention and availability of promising molecularly targeted therapies may change this dismal picture. These demands lead for developing new effective strategies with focusing on tumor cells and minimum side effects. Targeted cancer therapies have been defined as a new type of emerging treatments. This article provides an overview of: the characteristics and function of signal transduction pathway and emerging RTKs for targeted cancer therapies and therapy targeted at Ras/Raf/MEK/ERK Pathways and PI3k-Akt-mTOR-pathways. Future research in this area will maximize clinical benefit while minimizing the toxicity and cost through utilization of novel targeted agents.
Keywords
Cancer, Targeted Therapies, Small Molecule Inhibitors, Monoclonal Antibodies, Ras Pathways
To cite this article
Getu Melesie Taye, Review on: Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy, Journal of Cancer Treatment and Research. Vol. 7, No. 4, 2019, pp. 69-76. doi: 10.11648/j.jctr.20190704.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Chang DK, Wu C and Huang CT (2006). Targeted Therapy for Cancer. Journal of Cancer Molecules 2 (2): 57-66.
[2]
Bhatt AN, Mathur R, Farooque A, et al (2010). Cancer biomarkers - Current perspectives. Indian J Med Res 132: 129-149.
[3]
Ouhtit A, Lochan R, Shubha K (2013). Simultaneous Inhibition of Cell-Cycle, Proliferation, Survival, Metastatic Pathways and Induction of Apoptosis in Breast Cancer Cells by a Phytochemical Super-Cocktail: Genes That Underpin Its Mode of Action. Journal of Cancer 4 (9): 703-715.
[4]
Kakde D, Jain D, Shrivastava V et al (2011). Cancer Therapeutics Opportunities, Challenges and Advances in Drug Delivery. Journal of Applied Pharmaceutical Science 01 (09): 01-10.
[5]
Sierra R, Cepero V and Giordano S (2010). Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Molecular Cancer 9 (75): 1-13.
[6]
Tanaka T, Tamura K. (2012). Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non–Small Cell Lung Cancer. J Phys Chem Biophys 2 (108): 1-9.
[7]
Hickman A., Graeser R, Vidic S, et al (2014). Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo. Biotechnol. J 9: 1115–1128.
[8]
Armando A, Clarisse M, Miguel F (2015). The epidemiology of cancer in Angola results from the cancer registry of the national oncology center of Luanda, Angola. Cancer 9 (510): 1-10.
[9]
Anajwala CC, Jani GK, Swamy SM (2010). Current trends of Nanotechnology for Cancer Therapy. International journal of pharmaceutical sciences and nanotechnology 3 (3): 1043-1056.
[10]
Bray F, Ferlay J, Soerjomataram I et al (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 68: 394–424.
[11]
Uma Devi P (1982). Basics of carcinogenesis. Health Administrator 17 (1): 16-24.
[12]
Thurston DE (2007). Chemistry and pharmacology of anticancer drugs. John Smith (editor), New York.
[13]
Behera D (2007). New Approach to the Treatment of Lung Cancer: The Molecular Targeted Therapy. The Indian Journal of Chest Diseases & Allied Sciences 49: 150-158.
[14]
Xu M, Shao J, Zeng Y (2013). Molecular classification and molecular targeted therapy of cancer. Front. Med 7 (2): 147–149.
[15]
Radiæ S, Stanojeviæ Z (2004). Pathogenesis of neoplastic. Arch Oncol 12 (1): 35-37.
[16]
Hanahan D and Weinberg RA (2000). The Hallmarks of Cancer. Cell 100: 57–70.
[17]
Hojjat-Farsangi M (2014). Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. Int. J. Mol. Scin 15: 13768-13801.
[18]
Carrasco-García, E. Saceda M. Martínez-Lacaci. I (2014). Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma. Cells 3: 199-235.
[19]
Bret B, Alex A (2008). Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy. Clin Cancer Res 14: 342-346.
[20]
Plotnikov A, Zehorai E, Procaccia SH, Seger R (2011). The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biophysica Acta 1813: 1619–1633.
[21]
Won Lee H, Yong Choi H, Min Joo K et al (2015). Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer. Int. J. Mol. Sci 16: 4471-4491.
[22]
Bari SB, Adhikari S, Surana SJ (2012). Tyrosine Kinase Receptor Inhibitors: A New Target for Anticancer Drug Development. Journal of PharmaSciTech 1 (2): 36-45.
[23]
Alexey G, Yusuf D, Hilal S. et al (2014). Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy. Cells 3: 563-591.
[24]
Ensari A, Jung A, Kirchner T (2008). KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453: 417–431.
[25]
Rastogi I, Rajanna S, Puri N (2013). Current Molecularly. Targeted Therapies against EGFR for Cancer. J Cancer Sci Ther 6: 1-3.
[26]
Jianming Z, Priscilla L and Nathanael S (2009). Targeting cancer with small molecule kinase inhibitors. Cancer 9: 28-39.
[27]
Amit M, Nishi K, and Shilpa G. (2014). Epidermal Growth Factor Receptor Inhibitors: Coming of Age. Journal of the moffitt cancer center. 21 (1): 74-79.
[28]
Eckstein N, Röper L, Haas B et al (2014). Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. Journal of Experimental & Clinical Cancer Research 33 (15): 1-10.
[29]
Michael E and Flanigan-Minnick A (2011). Mechanisms of action of commonly used drugs to treat cancer. Commun Oncol 8: 357–369.
[30]
Dietrich EM, Antoniades K (2012). Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. Hippokratia, 16 (3): 196-199.
[31]
Levitzki A, Klein SH. Signal transduction therapy of cancer (2010). Molecular Aspects of Medicine 31: 287–329.
[32]
Rafael J, Cepero V and Giordano S (2010). Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer 9 (75). 1-13.
[33]
Ang JE. Kaye SB. Molecular targeted therapies in treatment of ovarian cancer (2007). Advances in gene, molecular and cell cancer therapy 1 (1): 68-79.
[34]
Imai K and Takaoka A (2006). Comparing antibody and small-molecule therapies for cancer. Cancer 6: 714-727.
[35]
Mischel PS and Cloughesy TF (2003). Targeted Molecular Therapy of GBM. Brain Pathol 13: 52-61.
[36]
Roberts PJ and Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291–3310.
[37]
Ou SH (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 83: 407-421.
[38]
Casacó A, Fuente D, Ledón N, et al. Aymara Fernández and Tania Crombet. Anti-Epidermal Growth Factor/Epidermal Growth Factor Receptor Therapeutic Anti-cancer Drugs and the Wound Healing Process. J Cancer Sci Ther 2012, 4.10: 324-329. Antiepide.
[39]
Gerber DE (2008). Targeted Therapies: A New Generation of Cancer Treatments. American Family Physician, 77 (3): 311-319.
[40]
Olcay E, Giovannetti E and Godefridus J (2010). Peters Drug Delivery and Drug Resistance: EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. The Open Lung Cancer Journal 3: 26-33.
[41]
Calvo F, Agudo-Ibanez L and Crespo P (2010). The Ras-ERK pathway: Understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays 32: 412–421.
[42]
Santarpia L, Lippman SL, and El-Naggar AK (2012). Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert Opin Ther Targets 16 (1): 103–119.
[43]
Terry K, Copur MS (2013). Molecular Targeted Therapy of Hepatocellular Carcinoma. Journal of Cancer Therapy 4: 426-439.
[44]
Dancey J and Sausville EA (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Drug discovery 2: 296-314.
[45]
Cox AD, Der JC (1997). Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimica Biophysica Acta 1333: 51–71.
[46]
Debarshi Kar Mahapatra, Vivek Asati & Sanjay Kumar Bharti (2017). MEK inhibitors in oncology: a patent review (2015-Present), Expert Opinion on Therapeutic Patents 27 (8): 887-906.
[47]
CHIN‑CHENG SU (2018). Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways ONCOLOGY REPORTS 4 3102: 3102-3111.
[48]
McRee, A. J.; Sanoff, H. K.; Carlson, C.; Ivanova, A.; O’Neil, B. H. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest. New Drugs 2015, 33, 1225–1231.
[49]
Reuter CW, Morgan MA, and Bergmann L (2000). Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96 (5): 1655-1669.
[50]
Morgillo F and Lee HY (2007). Development of farnesyl transferase inhibitors as anticancer agents: current status and future. Cancer Therapy 5: 11-18.
[51]
Sharaf LH (2006). Current trends and recent advances in breast cancer drug therapy Cancer Therapy 4: 183-192.
[52]
Anuj G. Agrawal and Rakesh R. Somani (2011). Farnesyltransferase Inhibitor in Cancer Treatment, Current Cancer Treatment - Novel Beyond Conventional Approaches, ISBN: 978-953-307-397-2.
[53]
Wang AX, Qi XY (2013). Targeting RAS/RAF/MEK/ERK Signaling in Metastatic Melanoma. International Union of Biochemistry and Molecular Biology 65 (9): 748–758.
[54]
Ebia H, Costaa C, Faber AC (2013). PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. PNAS 110 (52): 21124–21129.
[55]
Matsuoka T and Yashiro M (2014). The Role of PI3K/Akt/mTOR signaling in Gastric Carcinoma. Cancers 6: 1441-1463.
[56]
Khan KH, Yap TA, Yan L et al (2013). PI3K-AKT-mTOR Pathway signaling network in cancer. Chin J Cancer 32 (5): 253-265.
[57]
Porta C, Paglino C and Mosca A (2014). Targeting PI3K/Akt/mToR signaling in cancer. Front. Oncol. 4 (64): 1-11.
[58]
Slomovitz BM and Coleman RL (2012). The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer. Clin Cancer Res 18 (21): 1–9.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186